BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 24240734)

  • 21. Array-based profiling of the lymphoma cell DNA methylome does not unequivocally distinguish primary lymphomas of the central nervous system from non-CNS diffuse large B-cell lymphomas.
    Vogt J; Wagener R; Montesinos-Rongen M; Ammerpohl O; Paulus W; Deckert M; Siebert R
    Genes Chromosomes Cancer; 2019 Jan; 58(1):66-69. PubMed ID: 30284345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preferential up-regulation of osteopontin in primary central nervous system lymphoma does not correlate with putative receptor CD44v6 or CD44H expression.
    Yuan J; Gu K; He J; Sharma S
    Hum Pathol; 2013 Apr; 44(4):606-11. PubMed ID: 23089492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of immunoglobulin transcription factors in primary intraocular lymphoma and primary central nervous system lymphoma.
    Coupland SE; Loddenkemper C; Smith JR; Braziel RM; Charlotte F; Anagnostopoulos I; Stein H
    Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):3957-64. PubMed ID: 16249468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.
    Knittel G; Liedgens P; Korovkina D; Pallasch CP; Reinhardt HC
    Eur J Haematol; 2016 Dec; 97(6):499-510. PubMed ID: 27526684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma.
    Tateishi K; Miyake Y; Kawazu M; Sasaki N; Nakamura T; Sasame J; Yoshii Y; Ueno T; Miyake A; Watanabe J; Matsushita Y; Shiba N; Udaka N; Ohki K; Fink AL; Tummala SS; Natsumeda M; Ikegaya N; Nishi M; Ohtake M; Miyazaki R; Suenaga J; Murata H; Aoki I; Miller JJ; Fujii Y; Ryo A; Yamanaka S; Mano H; Cahill DP; Wakimoto H; Chi AS; Batchelor TT; Nagane M; Ichimura K; Yamamoto T
    Cancer Res; 2020 Dec; 80(23):5330-5343. PubMed ID: 33067267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.
    Yamada S; Ishida Y; Matsuno A; Yamazaki K
    Leuk Lymphoma; 2015 Jul; 56(7):2141-5. PubMed ID: 25347427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding the molecular pathogenesis of primary central nervous system lymphoma by experimental animal models.
    Wu D; Liu D; Tateishi K; Qi F; Yang F; Ke C; You H
    J Cell Physiol; 2023 Oct; 238(10):2191-2205. PubMed ID: 37642377
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Nayyar N; White MD; Gill CM; Lastrapes M; Bertalan M; Kaplan A; D'Andrea MR; Bihun I; Kaneb A; Dietrich J; Ferry JA; Martinez-Lage M; Giobbie-Hurder A; Borger DR; Rodriguez FJ; Frosch MP; Batchelor E; Hoang K; Kuter B; Fortin S; Holdhoff M; Cahill DP; Carter S; Brastianos PK; Batchelor TT
    Blood Adv; 2019 Feb; 3(3):375-383. PubMed ID: 30723112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preferential expression of truncated isoforms of FOXP1 in primary central nervous system lymphoma.
    Courts C; Brunn A; Montesinos-Rongen M; Siemer D; Hans V; Paulus W; Wiestler OD; Küppers R; Siebert R; Deckert M
    J Neuropathol Exp Neurol; 2009 Sep; 68(9):972-6. PubMed ID: 19680146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas.
    Fischer L; Hummel M; Korfel A; Lenze D; Joehrens K; Thiel E
    Neuro Oncol; 2011 Oct; 13(10):1090-8. PubMed ID: 21803762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Whole-Exome Sequencing Revealed the Mutational Profiles of Primary Central Nervous System Lymphoma.
    Zhang R; Wei B; Hu Y; Lv W; Adilai A; Yang F; Zhang J; Cheng G
    Clin Lymphoma Myeloma Leuk; 2023 Apr; 23(4):291-302. PubMed ID: 36725383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYC(low)BCL2 (low) subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas.
    Brunn A; Nagel I; Montesinos-Rongen M; Klapper W; Vater I; Paulus W; Hans V; Blümcke I; Weis J; Siebert R; Deckert M
    Acta Neuropathol; 2013 Oct; 126(4):603-5. PubMed ID: 24061549
    [No Abstract]   [Full Text] [Related]  

  • 33. Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell.
    Montesinos-Rongen M; Brunn A; Bentink S; Basso K; Lim WK; Klapper W; Schaller C; Reifenberger G; Rubenstein J; Wiestler OD; Spang R; Dalla-Favera R; Siebert R; Deckert M
    Leukemia; 2008 Feb; 22(2):400-5. PubMed ID: 17989719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The genomic and transcriptional landscape of primary central nervous system lymphoma.
    Radke J; Ishaque N; Koll R; Gu Z; Schumann E; Sieverling L; Uhrig S; Hübschmann D; Toprak UH; López C; Hostench XP; Borgoni S; Juraeva D; Pritsch F; Paramasivam N; Balasubramanian GP; Schlesner M; Sahay S; Weniger M; Pehl D; Radbruch H; Osterloh A; Korfel A; Misch M; Onken J; Faust K; Vajkoczy P; Moskopp D; Wang Y; Jödicke A; Trümper L; Anagnostopoulos I; Lenze D; Küppers R; Hummel M; Schmitt CA; Wiestler OD; Wolf S; Unterberg A; Eils R; Herold-Mende C; Brors B; ; Siebert R; Wiemann S; Heppner FL
    Nat Commun; 2022 May; 13(1):2558. PubMed ID: 35538064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of Tim-1 in primary CNS lymphoma.
    Kishimoto W; Nishikori M; Arima H; Miyoshi H; Sasaki Y; Kitawaki T; Shirakawa K; Kato T; Imaizumi Y; Ishikawa T; Ohno H; Haga H; Ohshima K; Takaori-Kondo A
    Cancer Med; 2016 Nov; 5(11):3235-3245. PubMed ID: 27709813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy.
    Montesinos-Rongen M; Brunn A; Tuchscherer A; Borchmann P; Schorb E; Kasenda B; Altmüller J; Illerhaus G; Ruge MI; Maarouf M; Büttner R; Hansmann ML; Hallek M; Prinz M; Siebert R; Deckert M
    J Mol Diagn; 2020 Oct; 22(10):1300-1307. PubMed ID: 32745612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunoglobulin repertoire of primary lymphomas of the central nervous system.
    Montesinos-Rongen M; Purschke F; Küppers R; Deckert M
    J Neuropathol Exp Neurol; 2014 Dec; 73(12):1116-25. PubMed ID: 25383641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in Pathobiology of Primary Central Nervous System Lymphoma.
    Yang XL; Liu YB
    Chin Med J (Engl); 2017 Aug; 130(16):1973-1979. PubMed ID: 28776551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary central nervous system lymphoma: an update.
    Soussain C; Hoang-Xuan K
    Curr Opin Oncol; 2009 Nov; 21(6):550-8. PubMed ID: 19684518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathway analysis of primary central nervous system lymphoma.
    Tun HW; Personett D; Baskerville KA; Menke DM; Jaeckle KA; Kreinest P; Edenfield B; Zubair AC; O'Neill BP; Lai WR; Park PJ; McKinney M
    Blood; 2008 Mar; 111(6):3200-10. PubMed ID: 18184868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.